FocalTherics (NASDAQ:FOCL) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of FocalTherics (NASDAQ:FOCL) from a hold rating to a sell rating in a report issued on Saturday morning.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Finally, Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, FocalTherics presently has a consensus rating of “Hold” and a consensus target price of $7.75.

FocalTherics Stock Up 2.8%

NASDAQ FOCL opened at $4.76 on Friday. The stock has a 50-day moving average of $5.39. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40. The company has a market capitalization of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The company had revenue of $13.20 million for the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. Research analysts anticipate that FocalTherics will post -0.78 EPS for the current year.

Institutional Trading of FocalTherics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rock Springs Capital Management LP lifted its holdings in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 91,500 shares in the last quarter. Flax Pond Capital LLC purchased a new stake in FocalTherics during the 4th quarter valued at approximately $2,623,000. Leonteq Securities AG purchased a new stake in FocalTherics during the 4th quarter valued at approximately $313,000. Kovack Advisors Inc. bought a new stake in shares of FocalTherics during the fourth quarter valued at approximately $53,000. Finally, Lido Advisors LLC bought a new stake in shares of FocalTherics during the first quarter valued at approximately $40,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.